Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience.

Sulaiman N, Othman AZ, Shahril NS, Abdul Rashid AM, Md Noh MSF.

SAGE Open Med Case Rep. 2017 Dec 17;5:2050313X17749080. doi: 10.1177/2050313X17749080. eCollection 2017.


Tumor Lysis Syndrome in Patients with Hematological Malignancies.

Belay Y, Yirdaw K, Enawgaw B.

J Oncol. 2017;2017:9684909. doi: 10.1155/2017/9684909. Epub 2017 Nov 2. Review.


Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases.

Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases.

Chin Med J (Engl). 2017 Oct 20;130(20):2473-2488. doi: 10.4103/0366-6999.216416. No abstract available.


Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.

Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, Thienel U, Gunawardhana L.

Arthritis Rheumatol. 2017 Dec;69(12):2386-2395. doi: 10.1002/art.40233.


Gout: An old disease in new perspective - A review.

Ragab G, Elshahaly M, Bardin T.

J Adv Res. 2017 Sep;8(5):495-511. doi: 10.1016/j.jare.2017.04.008. Epub 2017 May 10. Review.


Naturally Occurring Compounds: New Potential Weapons against Oxidative Stress in Chronic Kidney Disease.

Signorini L, Granata S, Lupo A, Zaza G.

Int J Mol Sci. 2017 Jul 10;18(7). pii: E1481. doi: 10.3390/ijms18071481. Review.


Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F.

Arthritis Rheumatol. 2017 Sep;69(9):1903-1913. doi: 10.1002/art.40159. Epub 2017 Aug 4.


Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.

Yamaguchi A, Harada M, Yamada Y, Hashimoto K, Kamijo Y.

BMC Nephrol. 2017 May 18;18(1):162. doi: 10.1186/s12882-017-0572-z.


Treatment approaches and adherence to urate-lowering therapy for patients with gout.

Aung T, Myung G, FitzGerald JD.

Patient Prefer Adherence. 2017 Apr 19;11:795-800. doi: 10.2147/PPA.S97927. eCollection 2017. Review.


Management of Gout and Hyperuricemia in CKD.

Vargas-Santos AB, Neogi T.

Am J Kidney Dis. 2017 Sep;70(3):422-439. doi: 10.1053/j.ajkd.2017.01.055. Epub 2017 Apr 26.


Treatment Options for Gout.

Engel B, Just J, Bleckwenn M, Weckbecker K.

Dtsch Arztebl Int. 2017 Mar 31;114(13):215-222. doi: 10.3238/arztebl.2017.0215.


Risk of Febuxostat-Associated Myopathy in Patients with CKD.

Liu CT, Chen CY, Hsu CY, Huang PH, Lin FY, Chen JW, Lin SJ.

Clin J Am Soc Nephrol. 2017 May 8;12(5):744-750. doi: 10.2215/CJN.08280816. Epub 2017 Mar 16.


Use of febuxostat in the management of gout in the United Kingdom.

Waller A, Jordan KM.

Ther Adv Musculoskelet Dis. 2017 Feb;9(2):55-64. doi: 10.1177/1759720X16682010. Epub 2016 Dec 28. Review.


An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.

Bove M, Cicero AF, Veronesi M, Borghi C.

Vasc Health Risk Manag. 2017 Feb 8;13:23-28. doi: 10.2147/VHRM.S115080. eCollection 2017. Review.


The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.

Jutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK.

Semin Arthritis Rheum. 2017 Apr;46(5):594-600. doi: 10.1016/j.semarthrit.2016.10.009. Epub 2016 Nov 1.


Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study.

Ito H, Antoku S, Abe M, Omoto T, Shinozaki M, Nishio S, Mifune M, Togane M, Nakata M, Yamashita T.

Intern Med. 2016;55(22):3247-3256. Epub 2016 Nov 15.


Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A.

Ann Rheum Dis. 2017 May;76(5):811-820. doi: 10.1136/annrheumdis-2016-209213. Epub 2016 Nov 7.


An old disease with new insights: Update on diagnosis and treatment of gout.

Bitik B, Öztürk MA.

Eur J Rheumatol. 2014 Jun;1(2):72-77. Epub 2014 Jun 1. Review.


Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.

Li S, Yang H, Guo Y, Wei F, Yang X, Li D, Li M, Xu W, Li W, Sun L, Gao Y, Wang Y.

Sci Rep. 2016 Sep 8;6:33082. doi: 10.1038/srep33082.


Poorly controlled gout: who is doing poorly?

Chia FL.

Singapore Med J. 2016 Aug;57(8):412-4. doi: 10.11622/smedj.2016129.

Supplemental Content

Support Center